Given IL-6’s implication in disease states, several agents inhibiting the IL-6 signaling pathway have been developed as pharmacological treatments for some of these diseases, e.g., rheumatoid arthritis, Castleman’s disease and prostate cancer. The gene discussed is IL6; the disease is prostate carcinoma.